Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 403

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 403
---
 square meters (approximately 270 square feet) of shared office space under an indefinite term lease that may be terminated by either party with one -monthprior notice. NLS believes that its current office space is sufficient to meet its anticipated needs for the foreseeable future and is suitable for the conduct of its business; provided, however, that NLS may require additional space and facilities as its business expands. Legal Proceedings From time to time NLS may become involved in legal proceedings that arise in the ordinary course of business. During the period covered by the financial statements contained herein, NLS was not subject to any material legal proceedings that has had a material adverse effect on its financial position, except as described below. No assurance can be given that future litigation will not have a material adverse effect on NLS’s financial position. When appropriate in management’s estimation, NLS may record reserves in its financial statements for pending litigation and other claims. 201 Cambrex Corporation On December 1, 2023, NLS received a letter from Cambrex Corporation, stating that as of December 1, 2023, NLS had an overdue balance for services completed under certain proposals by and between the Company, Cambrex High Point, Inc. and Avista Pharma Solutions, Inc. in the aggregate amount of $492,723.23. On October 10, 2024, the Company successfully settled the outstanding claim through a debt purchase agreement with an accredited investor, in the amount of $200,013, which effectively resolved the creditor claim. Clinilabs, Inc. On August 21, 2024, the Company received a letter from Dunn Lambert LLC, the law firm representing Clinilabs, stating that a complaint had been filed in the Superior Court of New Jersey. The complaint concerns three unpaid invoices totaling $886,412.46, plus interest at a rate of 6%. On June 1, 2023, Clinilabs entered into a start -upagreement with NLS. On December 4, 2023, NLS received five credit notes and two invoices from Clinilabs pursuant to services performed by Clinilabs under the start -upagreement. Clinilabs demanded $793,112.46 from NLS for unpaid service fees. On October 10, 2024, the Company successfully settled the outstanding claim through a debt purchase agreement with an accredited investor, in consideration of $500,222.91 and 49,475 NLS Common Shares equal in value to $279,299.